Van Andel Research Institute
New Blood Test Could Identify Pancreatic Cancer Subtypes Responsive to Chemotherapy
The test uses the sTRA biomarker to differentiate between different subtypes of pancreatic cancer, including those that are resistant to chemotherapy.
Researchers combined a new and established biomarker to detect nearly 70 percent of pancreatic cancers with a less than 5 percent false-positive rate.